Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer

Saved in:
Bibliographic Details
Published in:American journal of health-system pharmacy 2022-05, Vol.79 (10), p.717-718
Main Author: Chung, Clement
Format: Article
Language:English
Subjects:
Ado-Trastuzumab Emtansine
Antibodies, Monoclonal, Humanized - adverse effects
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms - drug therapy
Female
Humans
Maytansine - adverse effects
Receptor, ErbB-2 - therapeutic use
Trastuzumab - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1079-2082
1535-2900
DOI:10.1093/ajhp/zxac008